Searching for a cure, Improving lives

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

Posted on: July 26th, 2017 | 3 comments

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function in the canine model (dogs). Golden Labradors are naturally affected by Duchenne muscular dystrophy so researchers chose them for mammalian trials, ahead of tests in humans. The new pre-clinical research carried out by researchers at the Royal Holloway in London and French scientists, showed that repairing the defective gene vastly improved the ability of dogs to run, walk and jump. The 12 dogs, who were not expected to live longer than six months, were treated as puppies and are still alive two years after the trial. In some cases, the dogs’ motor skills were indistinguishable from animals without the condition.

The potential microdystrophin therapy works by replacing a faulty gene with fully functioning DNA using a harmless virus, which ‘infects’ cells and alters their genetic code. Once repaired, the gene produces a protein which is essential for correct muscle functioning.

Action Duchenne CEO, Diana Ribeiro comments, “In this seminal article in the high-impact journal Nature Communications, this study showed that micrdystrophin gene therapy significantly increased the amount of dystrophin protein in the dogs’ muscles, which led to an improvement in muscle function. Furthermore, the therapy did not induce a severe immune response in these investigations. This is one of the few studies which has been published which shows long-term data in the canine model, this is important evidence underpinning the potential of microdystrophin gene therapy and the reason which Action Duchenne has provided significant funds, alongside our partners AFM and MDUK towards the UNITE-DMD clinical trial project. “

Experts said the results offered ‘real hope’ for boys born with the condition.

Professor George Dickson, who led the trial at Royal Holloway, said: “This is tremendously exciting progress towards a gene therapy for  Duchenne muscular dystrophy.  The studies in dogs have been spectacular and exceeded our expectations.”

Click here for the full article published in Nature Communications.

DSCF4734 (1)

What next?

In March 2017, Action Duchenne announced our funding of “UNITE-DMD”, the first gene therapy trials for Duchenne muscular dystrophy here in the UK.

From the very early days of Action Duchenne, we have supported research into gene therapy as a potential way of treating Duchenne muscular dystrophy. This area has seen significant progress in recent years, and now is the time to test its safety in people living with Duchenne, here in the UK.

This international collaboration will assess the safety of gene therapy in Duchenne, in a phase I/II clinical trial that will take place in both the UK and France. As these will be the first gene therapy trials for Duchenne in the UK, UNITE-DMD will be vital to test the safety of this technology.

Together with the principal funder Muscular Dystrophy UK, we are investing over £1.6m into UNITE-DMD. The French Muscular Dystrophy Association (AFM-Téléthon) is funding the French arm of the project.

Click here for full article about UNITE-DMD

As always the best place in the UK to get updates on all aspects of Duchenne is the annual Action Duchenne International Conference. This year the event is 10-12 November at the Hilton Birmingham Metropole.

 

3 Responses to “Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

  1. Sue Georgallides says:

    Phenomenal news! Such promising results! I hope the human trials can get underway very soon and receive the funding to roll out the therapy to all Duchenne sufferers. We live in hope of a cure for my little grandson Lucas White and every one else affected by Duchenne.

  2. Blanca says:

    If a trial was to be come up, would you guys consider a child from the U.S?

Leave a Reply

Your email address will not be published. Required fields are marked *

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

First draft of agenda announced – Action Duchenne International Conference

June 28th, 2017

We are extremely excited to announce the first draft of the agenda for the Action

Tell me more

Acceleron takes back drug rights from Celgene to start pulmonary push

September 21st, 2017

Acceleron’s long-running collaboration with Celgene on sotatercept has taken another turn, with an amendment of

Tell me more

Synpromics announces Gene Therapy research partnership with Solid Biosciences

September 21st, 2017

Sypromics have announced a new research partnership with Solid Biosciences. Under the terms of the agreement,

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne